Drug Hunter
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.
Home > GS-9876 (lanraplenib)
<< Back to February
SYK-selective kinase inhibitor
oral, completed Ph. I in HV
from optimization of prior candidate
ACS Med. Chem. Lett. Feb. 12, 2020
Gilead Sciences, Seattle, WA
GS-9876 (lanraplenib) (Gilead Sciences oral SYK selective kinase inhibitor clinical candidate)
Unlock this content with a Premium membership to read it now.
